In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
A revolutionary gene therapy treatment costing a staggering £1.65 million has been approved for NHS use, offering patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback